7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers

7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers

Targeted biologics have transformed systemic oncology by exploiting cell-surface tumor antigens with exquisite molecular specificity. Therapeutic antibodies span three distinct pharmacological classes:

1. Naked Monoclonal Antibodies (mAbs): Unconjugated immunoglobulins that block ligand-receptor signaling cascades, induce tumor cell apoptosis, and engage host immune effector functions (Antibody-Dependent Cellular Cytotoxicity [ADCC], Complement-Dependent Cytotoxicity [CDC], and Antibody-Dependent Cellular Phagocytosis [ADCP]).
2. Antibody-Drug Conjugates (ADCs): "Biological guided missiles" consisting of a tumor-targeting monoclonal antibody chemically tethered via a synthetic linker to an ultra-potent cytotoxic payload (e.g., topoisomerase I inhibitors, microtubule disruptors, or DNA-cleaving agents).
3. Bispecific Antibodies & Bispecific T-Cell Engagers (BiTEs): Recombinant constructs engineered with dual antigen-binding specificities that physically crosslink endogenous CD3+ cytotoxic T lymphocytes directly to tumor-associated antigens (TAAs), inducing MHC-independent cytolytic immunological synapses.

---

1. Monoclonal Antibody Engineering & Effector Functions

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains folded into functional domains:

• Fab (Fragment Antigen-Binding) Region: Contains the variable hypervariable complementarity-determining regions (CDRs) that determine antigen specificity and binding affinity.
• Fc (Fragment Crystallizable) Region: The constant domain that interacts with host immune receptors (Fc-gamma Receptors [Fc-gamma-R]) on Natural Killer (NK) cells, macrophages, and neutrophils, or binds C1q to initiate the classical complement cascade.

+-----------------------------------------------------------------------------+
|                     ANTIBODY STRUCTURAL ANATOMY & ISOTYPES                  |
|                                                                             |
|            [Fab Region]                        [Fc Region]                  |
|         Antigen Recognition                Effector Functions               |
|                                                                             |
|        V_L  +-------+  V_H                     C_H2 +-------+               |
|        ===> | CDRs  | <===                     ===> | N-Gly | <=== Asn297   |
|             +-------+                               +-------+     Glycosyl- |
|              /     \                                    |         ation     |
|          C_L        C_H1                            +-------+               |
|             \       /                               | C_H3  |               |
|           [Hinge Region]                            +-------+               |
|          - Disulfide bonds -                       /         \              |
|                                              [Fc-gamma-RIIIa]    [C1q]      |
|                                                (NK Cells)     (Complement)  |
|                                                    |                |       |
|                                                  [ADCC]           [CDC]     |
+-----------------------------------------------------------------------------+

Antibody Isotypes and Glycoengineering

• IgG1 Isotype: Highly potent inducer of ADCC via Fc-gamma-RIIIa (CD16a) on NK cells and CDC via C1q complement fixation. Standard isotype for anti-tumor mAbs where immune-mediated destruction is desired (e.g., rituximab, trastuzumab, cetuximab, daratumumab).
• IgG2 Isotype: Minimal Fc receptor binding and weak complement activation; selected when simple receptor antagonism is required without immune effector destruction (e.g., panitumumab).
• IgG4 Isotype: Exhibits low affinity for Fc-gamma receptors and C1q; undergoes dynamic Fab-arm exchange in vivo; ideal for checkpoint inhibitors (e.g., pembrolizumab, nivolumab) where target receptor blockade is required without destroying host T lymphocytes.
• Afucosylation (Glycoengineering): Enzymatic or genetic removal of core fucose from the N-glycan at residue Asparagine-297 (Asn297) of the Fc domain prevents steric hindrance and increases binding affinity to Fc-gamma-RIIIa by up to 50-fold. This dramatically amplifies ADCC efficacy (e.g., Obinutuzumab vs. rituximab; Mogamulizumab anti-CCR4).

Nomenclature Systems (Historical vs. Modern WHO)

• Historical WHO Stems: -omab (100% murine; highest HAMA [human anti-mouse antibody] immunogenicity), -ximab (chimeric ~65% human; e.g., rituximab, cetuximab), -zumab (humanized ~90-95% human; e.g., trastuzumab), -umab (fully human 100%; e.g., panitumumab, daratumumab).
• Modern WHO Stems (2022+ System): -tug (unmodified immunoglobulin), -bart (artificial/engineered antibody), -ment (antibody fragment), -mig (multi-specific immunoglobulin).

---

2. Naked Monoclonal Antibodies in Clinical Practice

+-----------------------------------------------------------------------------+
|               MASTER NAKED MONOCLONAL ANTIBODY PRACTICE MATRIX              |
+-----------------------------------------------------------------------------+
| 1. HER2 / ERBB2 AXIS: TRASTUZUMAB & PERTUZUMAB                              |
|    - Mechanism: Trastuzumab binds HER2 Subdomain IV (inhibits cleavage,     |
|      activates ADCC). Pertuzumab binds Subdomain II (prevents HER2-HER3     |
|      heterodimerization). Landmark CLEOPATRA trial established dual blockade.|
|    - Cardiotoxicity Profile: Type II (Non-anthracycline) Cardiotoxicity:    |
|      * Non-dose dependent; ultrastructurally normal myocytes; REVERSIBLE.   |
|      * Manifests as asymptomatic drop in LVEF. Monitor baseline & Q3M ECHO. |
|      * Hold Criteria: LVEF drop >= 16% from baseline, OR LVEF below LLN     |
|        (<50%) with absolute drop >= 10% from baseline.                      |
|-----------------------------------------------------------------------------|
| 2. EGFR / HER1 AXIS: CETUXIMAB & PANITUMUMAB                                |
|    - Indication: Metastatic Colorectal Cancer (mCRC), HNSCC                 |
|    - Pharmacogenomic Requirement: STRICT ALL-RAS WILD-TYPE (KRAS & NRAS     |
|      Exons 2, 3, 4 WT) required for efficacy in mCRC. BRAF V600E resistance.|
|    - Infusion Reaction Differences:                                         |
|      * Cetuximab (Chimeric IgG1): High risk (~3-5% Grade 3-4); mediated by  |
|        pre-existing IgE antibodies against galactose-alpha-1,3-galactose     |
|        (alpha-gal) induced by Lone Star tick bites. Mandatory H1-antihistamine|
|      * Panitumumab (Fully Human IgG2): Low risk (<1%); no routine premeds.  |
|    - Signature Toxicity: Acneiform papulopustular rash; Hypomagnesemia      |
|      secondary to TRPM6 channel blockade in renal distal convoluted tubule. |
|-----------------------------------------------------------------------------|
| 3. CD20 TARGETING: RITUXIMAB & OBINUTUZUMAB                                 |
|    - Indications: B-Cell Non-Hodgkin Lymphomas (DLBCL, FL), CLL             |
|    - Black Box Warnings:                                                    |
|      * HEPATITIS B REACTIVATION: Mandatory screening for HBsAg and anti-HBc;|
|        initiate prophylactic entecavir/tenofovir prior to start and continue|
|        for >= 12 months post-completion if HBsAg+ or anti-HBc+.             |
|      * Infusion-Related Reactions (cytokine release; premedicate with APAP, |
|        diphenhydramine, +/- corticosteroid; start infusion slowly).         |
|      * Progressive Multifocal Leukoencephalopathy (PML) via JC virus.       |
|      * Severe Mucocutaneous Reactions (SJS/TEN).                            |
|    - Obinutuzumab (Type II Glycoengineered CD20): Superior PFS over         |
|      rituximab in frontline CLL (CLL11) and Follicular Lymphoma (GALLIUM).  |
|-----------------------------------------------------------------------------|
| 4. CD38 TARGETING: DARATUMUMAB & ISATUXIMAB                                 |
|    - Indication: Multiple Myeloma (frontline and relapsed/refractory)       |
|    - TRANSFUSION MEDICINE INTERFERENCE (CRITICAL BCOP PEARL):               |
|      * CD38 is expressed at low levels on human Red Blood Cells (RBCs).     |
|      * Daratumumab binds reagent RBCs, causing FALSE-POSITIVE PANREACTIVITY |
|        in Indirect Antiglobulin Tests (IAT / indirect Coombs antibody screen)|
|      * Mitigation: Perform baseline RBC phenotype/genotype prior to start,  |
|        OR treat reagent RBCs with DITHIOTHREITOL (DTT) to denature surface  |
|        CD38 (Note: DTT destroys Kell antigens -> give Kell-negative units). |
|    - SPEP / IFE Interference: Appears as a small IgG-kappa monoclonal band. |
+-----------------------------------------------------------------------------+

---

3. Antibody-Drug Conjugates (ADCs)

ADCs deliver potent cytotoxic payloads directly to tumor cells displaying target surface antigens, minimizing systemic exposure to free cytotoxin.

+-----------------------------------------------------------------------------+
|                        ANATOMY & PHARMACOLOGY OF ADCs                       |
|                                                                             |
|       [TARGET-SPECIFIC mAb]                                                 |
|       - High antigen affinity; minimal cross-reactivity with normal tissues |
|       - Rapid internalization upon receptor binding via endocytosis         |
|                                                                             |
|       [SYNTHETIC CHEMICAL LINKER]                                           |
|       - Cleavable Linkers:                                                  |
|         * Protease-sensitive (Valine-Citrulline; cleaved by Cathepsin B)    |
|         * Acid-labile (Hydrazone; cleaved in acidic endosomes pH 4.5-5.0)   |
|         * Glutathione-sensitive (Disulfide exchange in cytoplasm)           |
|         * Release UNCHARGED, MEMBRANE-PERMEABLE PAYLOADS -> BYSTANDER KILL! |
|       - Non-Cleavable Linkers (Thioether / SMCC):                           |
|         * Require complete lysosomal degradation of the entire mAb backbone |
|         * Release CHARGED, MEMBRANE-IMPERMEABLE CATABOLITES (Lysine-linker- |
|           toxin) -> NO BYSTANDER EFFECT; lower off-target systemic toxicity |
|                                                                             |
|       [POTENT CYTOTOXIC PAYLOAD (IC50 in sub-nanomolar range)]              |
|       - Microtubule Inhibitors: Auristatins (MMAE, MMAF), Maytansinoids     |
|         (DM1, DM4)                                                          |
|       - Topoisomerase I Inhibitors: SN-38 (irinotecan active metabolite),    |
|         Deruxtecan (DXd, exatecan derivative)                               |
|       - DNA-Damaging / Alkylating Agents: Calicheamicin, Pyrrolobenzo-      |
|         diazepine (PBD) dimers                                              |
|                                                                             |
|       [DRUG-TO-ANTIBODY RATIO (DAR)]                                        |
|       - Average number of payload molecules conjugated per antibody (2 to 8)|
+-----------------------------------------------------------------------------+

The Bystander Killing Effect

When an ADC with a cleavable linker is internalized and cleaved inside an antigen-positive tumor cell, the released lipophilic, uncharged payload (DXd, MMAE, SN-38) can passively diffuse across the cell membrane into the extracellular space. It then enters adjacent neighboring tumor cells within the heterogeneous tumor microenvironment—killing adjacent cells regardless of whether they express the target antigen. In contrast, non-cleavable linkers (T-DM1) generate charged lysine adducts that remain trapped inside the primary target cell.

Master ADC Clinical & Toxicological Reference

---

4. Bispecific T-Cell Engagers (BiTEs) & Multivalent Bispecific Antibodies

Bispecific antibodies possess two distinct antigen-binding domains, physically recruiting cytotoxic effector cells directly to neoplastic targets without requiring MHC antigen presentation or T-cell costimulation.

+-----------------------------------------------------------------------------+
|                     BISPECIFIC ANTIBODY STRUCTURAL FORMATS                  |
|                                                                             |
|   [CANONICAL BiTE FORMAT]                  [FULL-LENGTH IgG-LIKE FORMAT]    |
|   (e.g., Blinatumomab)                     (e.g., Teclistamab, Epcoritamab, |
|                                             Glofitamab)                     |
|        scFv (Anti-CD19)                         Fab (Anti-TAA)   Fab (Anti-CD3)
|             \                                         \         /           |
|          Flexible Linker                                [Fc Domain]         |
|             /                                                |              |
|        scFv (Anti-CD3)                               [Silenced Fc /         |
|                                                       No ADCC/CDC]          |
|   - Ultra-short half-life (~2 hours)        - Extended half-life (days/wks) |
|   - Requires 28-day continuous IV infusion  - Administered weekly/biweekly  |
|     via ambulatory CADD pump                  subcutaneously or IV          |
+-----------------------------------------------------------------------------+

Master Bispecific Therapeutic Agents

1. Blinatumomab (CD19 x CD3 BiTE):
   • Indications: Relapsed/Refractory B-ALL and Minimal Residual Disease (MRD)-positive B-ALL in first or second complete remission (BLAST trial).
   • Continuous Infusion Logistics: Administered as a continuous intravenous infusion over 28 consecutive days per cycle via a portable ambulatory infusion pump.
   • Toxicity Mitigation & Step-Up Dosing: Initiate at 9 mcg/day on Days 1–7, then escalate to 28 mcg/day on Days 8–28 of Cycle 1, accompanied by mandatory Dexamethasone 20 mg IV premedication prior to start and dose escalation to prevent severe Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS).
   • Pharmacy Compounding Pearl (IV Solution Stabilizer): Blinatumomab readily adsorbs to the plastic surfaces of IV bags and administration tubing. Compounding requires adding IV Solution Stabilizer (IVSS / polysorbate 80) to the 0.9% sodium chloride diluent bag prior to adding blinatumomab to coat internal plastic surfaces and ensure accurate, reproducible drug delivery.
2. Teclistamab (BCMA x CD3) & Elranatamab (BCMA x CD3):
   • Indication: Relapsed/refractory Multiple Myeloma post >= 4 prior lines of therapy (including an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody).
   • Administration: Subcutaneous injection with a mandatory step-up dosing schedule and 48-hour inpatient monitoring post-dose under FDA REMS.
   • Signature Toxicities: CRS, ICANS, and profound hypogammaglobulinemia with opportunistic infections (CMV, PJP, fungal infections; mandatory monthly IVIG replacement for IgG < 400 mg/dL, PJP prophylaxis with TMP-SMX, and HSV/VZV prophylaxis with acyclovir).
3. Talquetamab (GPRC5D x CD3):
   • Indication: Relapsed/refractory Multiple Myeloma targeting G-protein coupled receptor class C group 5 member D.
   • On-Target Off-Tumor Toxicities: GPRC5D is expressed in keratinized tissues. Induces severe dysgeusia / ageusia (taste loss leading to profound weight loss), palmar-plantar desquamation / skin peeling, and onychodystrophy / nail loss.
4. Glofitamab & Epcoritamab (CD20 x CD3):
   • Indication: Relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) post >= 2 lines of systemic therapy.
   • Debulking Strategy (Glofitamab): Features a unique 2:1 structural format (two CD20 binding sites, one CD3). Requires mandatory pre-treatment with Obinutuzumab 1,000 mg IV on Day -7 prior to Glofitamab Cycle 1 Day 1 step-up dosing to debulk circulating and tissue B cells, drastically reducing subsequent CRS severity.
5. Amivantamab (EGFR x MET Bispecific Naked mAb):
   • Indication: NSCLC harboring EGFR exon 20 insertion mutations (PAPILLON) or common EGFR mutations post-osimertinib (MARIPOSA).
   • Administration: Day 1 infusion reactions occur in 60–70% of patients; requires split-dose administration over Day 1 and Day 2, along with mandatory antihistamine, antipyretic, and glucocorticoid premedications.